Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Santen Pharmaceutical Co ( (JP:4536) ).
Santen Pharmaceutical Co., Ltd. announced a share buyback plan to enhance shareholder returns and capital efficiency. The company plans to repurchase up to 19.8 million common shares, representing 5.8% of its outstanding shares, with a maximum expenditure of 35 billion yen. The buyback will occur between May 22, 2025, and November 5, 2025, through open-market purchases. This move is part of Santen’s strategy to return profits to shareholders and improve capital management.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen1900.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting eye health in more than 60 countries.
Average Trading Volume: 1,229,031
Technical Sentiment Signal: Hold
Current Market Cap: Yen499.5B
Find detailed analytics on 4536 stock on TipRanks’ Stock Analysis page.